Atea Pharmaceuticals, Inc.
AVIRHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. The $341.7M market capitalization puts AVIR squarely in small-cap range for its industry. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Market Cap
$341.7M
Beta
0.38
P/E (TTM)
—
P/E (Fwd)
-3.08
EPS (TTM)
$-2.11
EPS (Fwd)
$-1.39
ROE
-52.6%
ROA
-33.5%
Cash
$256.0M
Total Debt
$634,000
Free CF
-$87.7M
52W Change
32.2%
Annual Financials
Cash vs Debt
Atea Pharmaceuticals, Inc. holds $256.0M in cash against $634K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$87.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -52.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Atea Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing AVIR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.